查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1624430

全球能力細胞市場規模（按應用、類型、最終用戶、地區、範圍和預測）

Global Competent Cells Market Size By Application, By Type, By End User, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

感受態細胞市場規模及預測

預計 2024 年感受態細胞市場規模將達到 19.1 億美元，2031 年將達到 40.4 億美元，2024-2031 年預測期內的複合年增長率為 9.80%。

推動全球感受態細胞市場的因素

感受態細胞市場的市場推動因素受到多種因素的影響。

研發活動：

生物技術和分子生物學研究的進步推動了對感受態細胞的需求。

生物製藥領域的成長：

不斷擴大的生物製藥市場推動了對用於生產治療性蛋白質、抗體和疫苗等生物製藥的感受態細胞的需求日益增長。

增加生命科學投資：

對生命科學研究的投資，特別是在合成生物學、基因組學和個人化醫療等領域的投資，正在促進感受態細胞市場的擴大，因為這些領域主要依賴分子克隆方法。

對重組DNA技術的需求日益增加：

重組 DNA 技術已被廣泛應用於基因編輯、基因治療和基因改造生物 (GMO) 的創造等各種應用，該技術嚴重依賴感受態細胞。

技術開發：

市場發展將受到細胞轉化方法技術持續發展的推動，包括提高轉化效率和生成與各種克隆載體相容的新型感受態細胞系。

CRISPR 技術的快速應用：

CRISPR/Cas9 基因編輯技術在治療和研究環境中的應用日益廣泛，推動了對適合基於 CRISPR 的研究的感受態細胞的需求。

個人化醫療的需求日益增長：

基因編輯和基因治療應用需要感受態細胞。個人化醫療的趨勢取決於我們瞭解每個人獨特基因組成的能力。

環境和永續性問題：

人們對環境永續性和綠色技術需求的日益關注推動了用於生產生物基產品和環境友善製程的感受態細胞的需求。

新興市場：

由於對生物技術研究的投資不斷增加以及生物製藥製造能力的發展，亞太地區、拉丁美洲和中東的新興市場具有巨大的成長潛力。

監管狀況：

隨著公司為其研究和製造流程尋求合規解決方案，基因改造作物 (GMO) 的使用和生物製藥開發受到法規的約束，這些法規影響了對感受態細胞的需求。

限制全球感受態細胞市場的因素

感受態細胞市場面臨多種限制和課題。這些包括：

成本高：

開發感受態細胞的成本很高，因為它需要特定的材料和複雜的製造技術。這可能使資源較少的組織或規模較小的實驗室難以獲得感受態細胞。

技術限制：

儘管取得了進展，但仍存在影響感受態細胞的有效性和可靠性的技術障礙。感受態細胞的性能會受到穩定性、與各種 DNA 構建體的兼容性以及轉化效率等因素的影響。

監管障礙：

生產和銷售感受態細胞的公司可能會面臨課題，因為對於使用基因改造生物 (GMO) 和工程細胞有嚴格的規定和監督。法規遵從性增加了開發和商業化過程的複雜性和成本。

衝突：

感受態細胞產業競爭相當激烈，許多老牌公司和新進者都提供類似的產品。價格和利潤率可能因競爭而下降，使得企業更難脫穎而出並維持市場佔有率。

道德問題：

基因改造生物的使用可能會引發倫理問題，尤其是在某些地區和經濟領域。公眾輿論和監管機構對基因改造生物的看法可能會影響市場對我們的感受態細胞產品的需求和接受度。

供應鏈中斷：

生產流程的變化或原材料的短缺可能會擾亂供應鏈，影響熟練勞動力的可用性並影響定價和市場穩定。

限量招募：

儘管感受態細胞具有許多優點，但一些實驗室可能不願意使用它們，因為擔心工作流程整合、需要專門的技術知識以及重組基因技術相關的風險。

目錄

第1章 全球感受態細胞市場簡介

  • 市場概況
  • 調查範圍
  • 先決條件

第 2 章執行摘要

第3章 VERIFIED MARKET RESEARCH研究方法

  • 數據挖掘
  • 驗證
  • 一次資料
  • 數據源列表

第4章 感受態細胞的全球市場展望

  • 概述
  • 市場動態
    • 促進因素
    • 阻礙因素
    • 機會
  • 波特的五力模型
  • 價值鏈分析
  • 監管框架

第5章 全球感受態細胞市場（依應用）

  • 概述
  • 複製
    • 亞克隆和常規克隆
    • 噬菌體展示文庫構建
    • 有毒/不穩定 DNA 克隆
    • 高通量克隆
  • 蛋白質表現
  • 其他
    • 突變介紹
    • 大型質粒轉化
    • 單股 DNA 生成
    • 慢病毒載體生產

第6章 全球感受態細胞市場依類型

  • 概述
  • 化學感受態細胞
  • 電感受態細胞

第 7 章 全球感受態細胞市場（依最終用戶劃分）

  • 概述
  • 學術研究所
  • 製藥和生物技術公司
  • 合同研究所

第 8 章 全球感受態細胞市場（按地區）

  • 概述
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 亞太其他地區
  • 世界其他地區
    • 拉丁美洲
    • 中東/非洲

第9章全球感受態細胞市場：競爭格局

  • 概述
  • 企業市佔率
  • 供應商情況
  • 主要發展策略

第10章 公司簡介

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Promega Corporation
  • Takara Bio, Inc.
  • New England Biolabs, Inc.
  • Bio-Rad Laboratories, Inc.
  • Transgen Biotech, Inc.
  • Agilent Technologies, Inc.
  • Illumina, Inc.
  • Zymo Research
  • Qiagen N.V.
  • Genscript Biotech Corporation
  • Origene Technologies, Inc.

第 11 章 附錄

  • 相關報導
簡介目錄
Product Code: 24314

Competent Cells Market Size And Forecast

Competent Cells Market size was valued at USD 1.91 Billion in 2024 and is projected to reach USD 4.04 Billion by 2031, growing at a CAGR of 9.80% during the forecasted period 2024 to 2031.

Global Competent Cells Market Drivers

The market drivers for the Competent Cells Market can be influenced by various factors. These may include:

Research and Development Activities:

The need for competent cells is driven by advances in biotechnology and molecular biology research, as these cells are necessary for a variety of molecular cloning and gene expression studies.

Increase in the Biopharmaceutical Sector:

The need for competent cells to produce biopharmaceuticals-such as therapeutic proteins, antibodies, and vaccines-is fueled by the growing market for these biologics.

Rising Life Sciences Investments:

Since these areas mostly rely on molecular cloning methods, investments in life sciences research-particularly in areas like synthetic biology, genomics, and personalized medicine-contribute to the market expansion of competent cells.

Growing Need for Technology Using Recombinant DNA:

Recombinant DNA technology, which is widely employed in many different applications like gene editing, gene therapy, and the creation of genetically modified organisms (GMOs), depends heavily on competent cells.

Technological Developments:

Market expansion is fueled by ongoing technological developments in cell transformation methods, such as the creation of novel competent cell strains with enhanced transformation efficiency and compatibility with various cloning vectors.

Rapid CRISPR Technology Adoption:

The increasing use of CRISPR/Cas9 gene editing technology in therapeutic and research settings raises the need for competent cells appropriate for CRISPR-based studies.

The Need for Personalized Medicine Is Increasing:

Competent cells are necessary for gene editing and gene therapy applications because of the trend toward personalized treatment, which depends on our ability to understand each person's unique genetic composition.

Concerns for the Environment and Sustainability:

The demand for competent cells employed in the creation of bio-based goods and environmentally friendly processes is driven by the growing concerns about environmental sustainability and the need for green technology.

Emerging Markets:

As a result of rising investments in biotechnology research and developing biopharmaceutical manufacturing capacities, emerging markets in Asia-Pacific, Latin America, and the Middle East offer substantial growth prospects.

Regulatory Landscape:

As businesses look for compliance solutions for their research and manufacturing processes, the usage of genetically modified organisms (GMOs) and the development of biopharmaceuticals are subject to regulations that impact the demand for competent cells.

Global Competent Cells Market Restraints

Several factors can act as restraints or challenges for the Competent Cells Market. These may include:

High Cost:

Developing competent cells can be expensive due to the need for specific materials and complex manufacturing techniques. This may make them less accessible to organizations with fewer finances or smaller research labs.

Technological Limitations:

Despite developments, there may still be technological barriers that affect the effectiveness and dependability of competent cells. Their performance can be affected by factors like stability, compatibility with different DNA constructions, and transformation efficiency.

Regulatory Obstacles:

Businesses that produce and distribute competent cells may face difficulties due to strict rules and oversight around the use of genetically modified organisms (GMOs) or altered cells. Regulation adherence increases the process of development and commercialization's complexity and expense.

Competition:

A number of well-established businesses and recent entrants provide comparable goods in the competent cells industry, which is reasonably competitive. Prices and profit margins may decline due to competition, making it difficult for businesses to stand out from the competition and hold onto market share.

Ethical Concerns:

The use of genetically modified organisms may raise ethical questions, particularly in some areas or sectors of the economy. Market demand and acceptability of competent cell products can be influenced by public and regulatory views on genetically modified organisms.

Supply Chain Disruptions:

Changes in the production process or a scarcity of raw materials can cause supply chain disruptions that affect the availability of skilled labor and affect pricing and market stability.

Limited Adoption:

Although competent cells have many advantages, some research labs may be reluctant to use them because of worries about workflow integration, the need for specialized technical knowledge, or perceived hazards related to genetic modification methods.

Global Competent Cells Market: Segmentation Analysis

The Global Competent Cells Market is segmented on the basis of Application, Type, End User, And Geography.

Competent Cells Market, By Application

  • Cloning
  • Subcloning& Routine Cloning
  • Phage Display Library Construction
  • Toxic/Unstable DNA Cloning
  • High-Throughput Cloning
  • Protein Expression
  • Others
  • Mutagenesis
  • Large Plasmid Transformation
  • Single-Stranded DNA Production
  • Lentiviral Vector Production

Based on Application, the market is bifurcated into Cloning, Protein Expression, and Others. The Cloning segment is expected to hold the largest market share. The factors can be attributed to the growing research on cloning driven by government support and funding.

Competent Cells Market, By Type

  • Chemically Competent Cells
  • Electro Competent Cells

Based on Type, the market is bifurcated into Chemically Competent Cells and Electro Competent Cells. The Chemically Competent Cells segment is predicted to hold the largest market share in the forecasted period. The Electro Competent Cells segment is anticipated to grow with the highest CAGR as Electro Competent Cells are suitable for many molecular biology applications like the generation of cDNA libraries as they possess high transformation efficiencies.

Competent Cells Market, By End User

  • Academic Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations

Based on End User, the market is bifurcated into Academic Research Institutes, Pharmaceutical & Biotechnology Companies, and Contract Research Organizations. The Pharmaceutical & Biotechnology Companies segment is anticipated to hold the largest market share. The factors can be credited for increasing investments in research for developing genomics and proteomics-based products.

Competent Cells Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the Global Competent Cells Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America owing to the growing number of R&D activities in this region.

Key Players

  • The major players in the Competent Cells Market are:
  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Promega Corporation
  • Takara Bio Inc.
  • New England Biolabs Inc.
  • Bio-Rad Laboratories Inc.
  • Transgen Biotech Inc.
  • Agilent Technologies Inc.
  • Illumina Inc.
  • Zymo Research
  • Qiagen N.V.
  • Genscript Biotech Corporation
  • and Origene Technologies Inc.
  • Thermo Fisher Scientific
  • Merck KGaA
  • New England Biolabs
  • Takara Bio
  • Agilent Technologies

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL COMPETENT CELLS MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL COMPETENT CELLS MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis
  • 4.5 Regulatory Framework

5 GLOBAL COMPETENT CELLS MARKET, BY APPLICATION

  • 5.1 Overview
  • 5.2 Cloning
    • 5.2.1 Subcloning& Routine Cloning
    • 5.2.2 Phage Display Library Construction
    • 5.2.3 Toxic/Unstable DNA Cloning
    • 5.2.4 High-Throughput Cloning
  • 5.3 Protein Expression
  • 5.4 Others
    • 5.4.1 Mutagenesis
    • 5.4.2 Large Plasmid Transformation
    • 5.4.3 Single-Stranded DNA Production
    • 5.4.4 Lentiviral Vector Production

6 GLOBAL COMPETENT CELLS MARKET, BY TYPE

  • 6.1 Overview
  • 6.2 Chemically Competent Cells
  • 6.3 Electro Competent Cells

7 GLOBAL COMPETENT CELLS MARKET, BY END USER

  • 7.1 Overview
  • 7.2 Academic Research Institutes
  • 7.3 Pharmaceutical & Biotechnology Companies
  • 7.4 Contract Research Organizations

8 GLOBAL COMPETENT CELLS MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East and Africa

9 GLOBAL COMPETENT CELLS MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Share
  • 9.3 Vendor Landscape
  • 9.4 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Thermo Fisher Scientific, Inc.
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Merck KGaA
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 Promega Corporation
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Takara Bio, Inc.
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 New England Biolabs, Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Bio-Rad Laboratories, Inc.
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 Transgen Biotech, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Agilent Technologies, Inc.
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments
  • 10.9 Illumina, Inc.
    • 10.9.1 Overview
    • 10.9.2 Financial Performance
    • 10.9.3 Product Outlook
    • 10.9.4 Key Developments
  • 10.10 Zymo Research
    • 10.10.1 Overview
    • 10.10.2 Financial Performance
    • 10.10.3 Product Outlook
    • 10.10.4 Key Developments
  • 10.11 Qiagen N.V.
    • 10.11.1 Overview
    • 10.11.2 Financial Performance
    • 10.11.3 Product Outlook
    • 10.11.4 Key Developments
  • 10.12 Genscript Biotech Corporation
    • 10.12.1 Overview
    • 10.12.2 Financial Performance
    • 10.12.3 Product Outlook
    • 10.12.4 Key Developments
  • 10.13 Origene Technologies, Inc.
    • 10.13.1 Overview
    • 10.13.2 Financial Performance
    • 10.13.3 Product Outlook
    • 10.13.4 Key Developments

11 Appendix

  • 11.1 Related Reports